AU2006249816A1 - Treatment of eye disorders with sirtuin modulators - Google Patents

Treatment of eye disorders with sirtuin modulators Download PDF

Info

Publication number
AU2006249816A1
AU2006249816A1 AU2006249816A AU2006249816A AU2006249816A1 AU 2006249816 A1 AU2006249816 A1 AU 2006249816A1 AU 2006249816 A AU2006249816 A AU 2006249816A AU 2006249816 A AU2006249816 A AU 2006249816A AU 2006249816 A1 AU2006249816 A1 AU 2006249816A1
Authority
AU
Australia
Prior art keywords
compound
formula
further embodiment
attendant definitions
sirtuin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006249816A
Other languages
English (en)
Inventor
Peter Elliott
Philip Lambert
David J. Livingston
Michael Milburn
Karl D. Normington
Christoph H. Westphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of AU2006249816A1 publication Critical patent/AU2006249816A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2006249816A 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators Abandoned AU2006249816A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US60/684,252 2005-05-25
US73155005P 2005-10-28 2005-10-28
US60/731,550 2005-10-28
US78835806P 2006-03-30 2006-03-30
US60/788,358 2006-03-30
PCT/US2006/020406 WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Publications (1)

Publication Number Publication Date
AU2006249816A1 true AU2006249816A1 (en) 2006-11-30

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006249816A Abandoned AU2006249816A1 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Country Status (5)

Country Link
EP (1) EP1928440A2 (enExample)
JP (1) JP2008542296A (enExample)
AU (1) AU2006249816A1 (enExample)
CA (1) CA2609549A1 (enExample)
WO (1) WO2006127987A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
BRPI0912356A2 (pt) 2008-05-01 2015-10-06 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
WO2010037129A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
ES2567782T3 (es) * 2009-02-04 2016-04-26 Dsm Ip Assets B.V. Composiciones de resveratrol
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
JP5955750B2 (ja) * 2012-11-20 2016-07-20 株式会社東洋新薬 皮膚外用剤
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20160374908A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US9833398B2 (en) 2016-01-11 2017-12-05 The Procter & Gamble Company Method of treating a skin condition and compositions therefor
LT3416654T (lt) 2016-02-18 2022-01-10 Invirsa, Inc. 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas
WO2018030389A1 (ja) * 2016-08-08 2018-02-15 学校法人 慶應義塾 Ｎａｄ関連代謝産物の利用
ES2955713T3 (es) * 2016-09-13 2023-12-05 Megumi Tanaka Agente de mejora de la función visual, y método para mejorar la función visual
CN109982692A (zh) * 2016-11-14 2019-07-05 王明武 用于治疗眼表疾病的制剂和相关方法
CA3055755A1 (en) * 2017-03-07 2018-09-13 Cempra Pharmaceuticals, Inc. Compositions and methods for treating dry eye diseases
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
ES2949441T3 (es) 2018-03-27 2023-09-28 Invirsa Inc Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
US20220370484A1 (en) * 2019-06-25 2022-11-24 Senju Pharmaceutical Co., Ltd. Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr)
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0398925B1 (en) * 1988-01-19 1993-10-20 Children's Hospital Corporation Growth inhibiting agent and the use thereof
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
CA2350396C (en) * 1998-12-24 2010-06-29 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (ja) * 1999-03-31 2000-12-12 Sunstar Inc スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ES2190771B2 (es) * 2002-01-24 2004-03-01 Univ Alicante Procedimiento para la produccion de resveratrol en cultivos celulares.
JP2003252760A (ja) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp 網膜疾患治療剤および／または予防剤
CN1220486C (zh) * 2002-11-15 2005-09-28 董英杰 白藜芦醇类化合物的β－环糊精或其衍生物的包合物及其制备方法
JP4564920B2 (ja) * 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
CN1925862A (zh) * 2003-10-10 2007-03-07 雷斯弗洛吉克斯公司 与egr－1增强子元件有关的疾病的治疗
DE102004002787A1 (de) * 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Also Published As

Publication number Publication date
EP1928440A2 (en) 2008-06-11
WO2006127987A3 (en) 2008-04-17
CA2609549A1 (en) 2006-11-30
JP2008542296A (ja) 2008-11-27
WO2006127987A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AU2006230478B2 (en) Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
AU2006249816A1 (en) Treatment of eye disorders with sirtuin modulators
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
JP5315252B2 (ja) 眼科用薬物の輸送に有用なゲル
Adelli et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability
CN1882508B (zh) 水溶性二萜的制备方法及其应用
JP6946001B2 (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
KR20170097601A (ko) 생물활성, 나노입자포집된 항산화제의 운반
EP2271334B1 (en) Methods of treating fibrotic disorders
KR20150058159A (ko) 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료
CN118891032A (zh) 用于延长释放非诺贝特的微球
KR101771483B1 (ko) 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물
Cetin A review on ophthalmic delivery systems containing flavonoids for the treatment of eye diseases
JP6502393B2 (ja) ニコチンと酸化セリウムとのナノ粒子複合体及びその使用
US20040192745A1 (en) Method of treating amytrophic lateral sclerosis using melatonin
KUMAR et al. NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS
Khin Development of fenofibrate/cyclodextrin complex loaded eudragit nanoparticles for ocular delivery
EP4074319A1 (en) Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye
EP4611740A1 (en) Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction
HK1098450B (en) Process for preparing water soluble diterpenes and their applications

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application